The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).
 
Dan Liu
No Relationships to Disclose
 
Lin Shen
No Relationships to Disclose
 
Sumitra Ananda
Honoraria - MSD
 
Dan Cao
No Relationships to Disclose
 
Catherine HyeWon Han
No Relationships to Disclose
 
Jermaine Coward
Research Funding - AstraZeneca (Inst)
 
Yee Chao
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Prashanth Hari Dass
No Relationships to Disclose
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Ipsen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche
 
Adnan Nagrial
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Yuan Huang
No Relationships to Disclose
 
Vinod Ganju
Honoraria - AstraZeneca; Roche/Genentech
 
Xiaobing Chen
No Relationships to Disclose
 
Deirdre J. Cohen
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Guardant Health
Research Funding - Eisai (Inst); Merck (Inst); Viome (Inst)
 
Rajiv Kumar
No Relationships to Disclose
 
Li-Yuan Bai
Honoraria - Ipsen; Ono Pharmaceutical
Consulting or Advisory Role - Amgen; Astellas Pharma
Research Funding - Eisai
 
Ying Yuan
No Relationships to Disclose
 
Tai-Jan Chiu
No Relationships to Disclose